

***Fiscal Year 2023 (FY23) Department of Defense Melanoma Research Program (MRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-MRP-IA</p>	<p>Investigators must be at or above the level of Postdoctoral Fellow or equivalent.</p> <p>Principal Investigators (PIs) new to the melanoma field are encouraged.</p>	<ul style="list-style-type: none"> • <i>Preproposal is required; application submission is by invitation only.</i> • Supports new ideas that represent innovative, high-risk/high-gain approaches to melanoma research that are beyond an incremental advancement. • Emphasis on innovation and impact. • Must address at least one of the FY23 MRP Focus Areas. • <i>Preliminary data are discouraged.</i> Inclusion of preliminary data other than serendipitous findings is not consistent with the exploratory/innovative nature of this award. • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$500,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): July 10, 2023 5:00 p.m. Eastern time (ET)</p> <p>Application: September 22, 2023 11:59 p.m. ET</p>
<p>Melanoma Academy Scholar Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-MRP-MASA</p>	<p>Investigators must be within 7 years of their first faculty-level appointment as of the full application submission deadline.</p>	<ul style="list-style-type: none"> • <i>A letter of intent is required; an invitation to submit a full application is not required.</i> • Supports the addition of new Scholars to the unique, interactive virtual <u>Melanoma Academy</u> that provides intensive mentoring, national networking, collaborations, and a peer group for early-career melanoma investigators. • Requires a Career Guide who is an experienced melanoma researcher with melanoma cancer funding. • The Career Guide is not required to be at the same institution as the Scholar. • The Career Guide must be committed to participating in the Melanoma Academy, including serving in advisory roles as requested by Academy Leadership. • Must address at least one of the FY23 MRP Focus Areas. • <i>Preliminary data are not required.</i> • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$550,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): August 31, 2023 5:00 p.m. ET</p> <p>Application: September 22, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Mid-Career Accelerator Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-MRP-MCAA</p>	<p>Investigators must be Assistant or Associate Professors (or equivalents) at least 7 years from their first faculty-level appointment.</p> <p>Instructors and Full Professors (or equivalents) are <u>not</u> eligible.</p>	<ul style="list-style-type: none"> • <i>A letter of intent is required; an invitation to submit a full application is not required.</i> • Supports mid-career researchers conducting impactful melanoma research. • Must address at least one of the FY23 MRP Focus Areas. • Must show evidence of at least one peer-reviewed source of extramural funding. • <i>Preliminary data relevant to melanoma are required.</i> • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$725,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): August 31, 2023 5:00 p.m. ET</p> <p>Application: September 22, 2023 11:59 p.m. ET</p>
<p>Team Science Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-MRP-TSA</p>	<p>At least two and up to three Investigators must partner in one overarching multidisciplinary research study.</p> <p>Independent Investigators must be at or above the level of Assistant Professor (or equivalent).</p> <p>Inclusion of at least one military, U.S. Department of Veterans Affairs, or Early-Career Investigator is encouraged.</p> <p>Postdoctoral fellows are not eligible to be Initiating nor Partnering PIs.</p>	<ul style="list-style-type: none"> • <i>A letter of intent is required; an invitation to submit a full application is not required.</i> • Supports new or existing partnerships to address a research problem or question in a manner that would be unachievable through separate efforts. • Intended to fund a broad range of studies including, but not limited to: <ul style="list-style-type: none"> ○ Correlative studies that are associated with an open/ongoing or completed clinical trial ○ Research involving the analysis of large and/or complex melanoma datasets ○ Projects focusing on bioengineering approaches to address diagnostics, high risk markers, dormancy, and/or metastasis ○ Research seeking to better understand and/or reduce inequities and disparities that impact melanoma patients and/or caregivers. • Emphasis on synergy, multidisciplinary research, and impact. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,250,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): August 31, 2023 5:00 p.m. ET</p> <p>Application: September 22, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none"> Applicants are encouraged but not required to collaborate with the melanoma community (e.g., melanoma patients, survivors, caregivers) to optimize research impact and translatability through inclusion of a patient advocate, partnership with a community-supporting organization, or establishment of a community advisory board. Must address at least one of the FY23 MRP Focus Areas. Preliminary data are required. Clinical trials are not allowed. 		
<p>Focused Program Award – Rare Melanomas</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-MRP-FPA-RM</p>	<p>Independent Investigators must be at or above the level of Associate Professor (or equivalent).</p> <p>Project Leader(s) for the complementary and synergistic research project(s) must be at or above the level of Assistant Professor (or equivalent).</p>	<ul style="list-style-type: none"> <i>A letter of intent is required; an invitation to submit a full application is not required.</i> Applications may propose projects across the entire research spectrum (biology, etiology, prevention, diagnosis and detection, prognosis, treatment, and quality of life) and must address a critical unmet need relevant to rare melanomas (uveal, acral, mucosal, pediatric, etc.). Supports a synergistic, multidisciplinary research program of at least two but not more than three distinct but complementary projects addressing an overarching question relevant to rare melanomas. Individual research projects may range from exploratory, hypothesis-developing studies through clinical trials. The research team assembled by the PI should be highly qualified and multidisciplinary, with an identified Project Leader(s) for the complementary and synergistic research project(s). 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$2,000,000 for direct costs. The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): August 31, 2023 5:00 p.m. ET</p> <p>Application: September 22, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
		<ul style="list-style-type: none">• Applicants are encouraged, but not required, to collaborate with the rare melanoma community to optimize research impact and translatability through inclusion of a patient advocate, partnership with a community-supporting organization, or establishment of a community advisory board.• <i>Clinical trials are allowed.</i>		